Potassium-competitive acid blocker versus proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding: Rationale and design of the randomized PROTECT- HBR trial
作者：Jinho Lee [1];Han-Su Park [2];Junghoon Lee [3];Kee Don Choi [4];Do-Yoon Kang [5];Jung-Min Ahn [6];Weon Kim [7];Jong-Young Lee [8];Young-Hyo Lim [9];Se Hun Kang [10];Sung Uk Kwon [11];Hanbit Park [12];Eue-Keun Choi [13];Soon Jun Hong [14];Byeong-Keuk Kim [15];Eun-Sun Jin [16];Jin-Ok Jeong [17];Chang-Wook Nam [18];Wang Soo Lee [19];Sang Min Kim [20];Kyoung-Ha Park [21];Sung-Ho Her [22];Eun-Seok Shin [23];Young Jin Choi [24];Tae-Hyun Yang [25];Sang-Hyun Kim [26];Jung-Won Suh [27];Hwan-Cheol Park [28];Yong-Hoon Yoon [29];Myeong-Ho Yoon [30];Seung-Jung Park [31];Duk-Woo Park [32];
DOI：10.1016/j.ahj.2025.04.001